About the role:
The mission of the CRUK National Biomarker Centre (NBC) is to discover, develop, validate and qualify biomarkers
that facilitate optimised treatment of patients with cancer. We are seeking an innovative and dynamic
Communications and Engagement Officer to join our Centre and lead our efforts to enhance the visibility of our
research and amplify awareness of the Centre’s capabilities and scientific excellence.
This is an exciting opportunity to join a globally recognised, patient facing cancer research centre focussed on improving cancer outcomes. You will play a key role in shaping how we communicate our research. You will strengthen the Centre’s profile nationally and internationally by developing engaging, high-quality content that showcases our research, our capabilities and our impact to encourage new collaborations and uplift fundraising so that we can do more, faster to achieve our goals.
As Communications and Engagement Officer, you will work closely with the Centre’s leadership and wider scientific community to elevate the Centre’s profile through creative, impactful communications.
Key Responsibilities:
About you:
You will be a creative and organised communications professional with excellent writing skills and the ability to turn complex scientific information into clear, compelling content for a variety of audiences. You will be confident managing multiple priorities, building relationships with stakeholders and working collaboratively in a fast-paced research environment.
You will have a degree in biosciences, communications, marketing, journalism or a related field OR equivalent relevant experience, together with experience in science-related communications.
If you are looking for a truly meaningful role where you can combine your creativity and strategic thinking to communicate research that drives towards improved outcomes for people affected by cancer, we would love to hear from you.
Why choose the Cancer Research UK National Biomarker Centre?
We are an internationally leading, highly specialised translational research centre within The University of Manchester (www.manchester.ac.uk), aligned with the Cancer Research UK Manchester Institute (www.cruk.manchester.ac.uk) and core-funded by Cancer Research UK (www.cancerresearchuk.org), the largest independent cancer research organisation in the world. In spring 2023, the NBC moved into the state-of-the-art Paterson Building, a £150 million flagship purpose-built biomedical research centre directly attached to The Christie NHS Foundation Trust in South Manchester (www.christie.nhs.uk), one of the largest cancer treatment centres in Europe. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes and a perfect location for a multidisciplinary and highly collaborative Cancer Biomarker Centre.
Agnostic to cancer type, the NBC discovers, develops, validates and qualifies biomarkers in preclinical models and in clinical studies and clinical trials that detect and diagnose cancers earlier, that determine prognosis and that predict and monitor therapy responses (efficacy and toxicity) to support optimised treatment of patients with cancer. Our advanced research programmes develop biomarkers in tissue and less invasive clinical samples such as blood (liquid biopsy). We use sophisticated bioinformatic and artificial intelligence solutions for the analysis and interpretation of integrated multi-modal laboratory biomarker and clinical data. We provide a highly specialised bridge between discovery science and clinical research and undertake a wide range of collaborative projects across Manchester, nationally and internationally.
To apply for this position please complete the online application via ‘Apply Now’. Please ensure you detail the names of two referees and ensure you submit your application before the closing date specified.
Please note this vacancy will close for applications at 18:00 hours on the closing date specified.
Informal enquiries can be made to the hiring manager.
FURTHER PARTICULARS